Search

Your search keyword '"Phillips, Gordon L."' showing total 49 results
Start Over Author "Phillips, Gordon L." Search Limiters Academic (Peer-Reviewed) Journals
49 results on '"Phillips, Gordon L."'

10. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia

Author

Litzow, Mark R., Tarima, Sergey, Pérez, Waleska S., Bolwell, Brian J., Cairo, Mitchell S., Camitta, Bruce M., Cutler, Corey S., de Lima, Marcos, DiPersio, John F., Gale, Robert Peter, Keating, Armand, Lazarus, Hillard M., Luger, Selina, Marks, David I., Maziarz, Richard T., McCarthy, Philip L., Pasquini, Marcelo C., Phillips, Gordon L., Rizzo, J. Douglas, Sierra, Jorge, Tallman, Martin S., and Weisdorf, Daniel J.

Published
2010
Full Text
View/download PDF

12. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement

Author

Maziarz, Richard T., Wang, Zhiwei, Zhang, Mei-Jie, Bolwell, Brian J., Chen, Andy I., Fenske, Timothy S., Freytes, Cesar O., Gale, Robert P., Gibson, John, Hayes-Lattin, Brandon M., Holmberg, Leona, Inwards, David J., Isola, Luis M., Khoury, Hanna J., Lewis, Victor A., Maharaj, Dipnarine, Munker, Reinhold, Phillips, Gordon L., Rizzieri, David A., Rowlings, Philip A., Saber, Wael, Satwani, Prakash, Waller, Edmund K., Maloney, David G., Montoto, Silvia, Laport, Ginna G., Vose, Julie M., Lazarus, Hillard M., and Hari, Parameswaran N.

Published
2013
Full Text
View/download PDF

13. Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia in First Remission

Author

Tallman, Martin S., Pérez, Waleska S., Lazarus, Hillard M., Gale, Robert Peter, Maziarz, Richard T., Rowe, Jacob M., Marks, David I., Cahn, Jean-Yves, Bashey, Asad, Bishop, Michael R., Christiansen, Neal, Frankel, Stanley R., García, Juan J., Ilhan, Osman, Laughlin, Mary J., Liesveld, Jane, Linker, Charles, Litzow, Mark R., Luger, Selina, McCarthy, Philip L., Milone, Gustavo A., Pavlovsky, Santiago, Phillips, Gordon L., Russell, James A., Saez, Ruben A., Schiller, Gary, Sierra, Jorge, Weiner, Roy S., Zander, Axel R., Zhang, Mei-Jie, Keating, Armand, Weisdorf, Daniel J., and Horowitz, Mary M.

Published
2006
Full Text
View/download PDF

16. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver

Author

Lavoie, Julye C., Connors, Joseph M., Phillips, Gordon L., Reece, Donna E., Barnett, Michael J., Forrest, Donna L., Gascoyne, Randy D., Hogge, Donna E., Nantel, Stephen H., Shepherd, John D., Smith, Clayton A., Song, Kevin W., Sutherland, Heather J., Toze, Cynthia L., Voss, Nicholas J.S., and Nevill, Thomas J.

Published
2005
Full Text
View/download PDF

18. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program

Author

Kernan, Nancy A., Bartsch, Glenn, Ash, Robert C., Beatty, Patrick G., Champlin, Richard, Filipovich, Alexandra, Gajewski, James, Hansen, John A., Henslee-Downey, Jean, McCullough, Jeffrey, McGlave, Philip, Perkins, Herbert A., Phillips, Gordon L., Sanders, Jean, Stroncek, David, Thomas, E. Donnall, and Blume, Karl G.

Subjects
Bone marrow -- Transplantation, Leukemia -- Care and treatment
Abstract

A bone marrow transplant from an unrelated donor can prolong the survival of patients with leukemia and other disorders affecting the bone marrow. Data were collected from the National Marrow Donor Program on 462 patients treated with bone marrow donated by an unrelated donor between Dec 1987 and Nov 1990. Most had some type of leukemia. Over 90% of the patients' grafts began functioning within 100 days of transplantation. Almost two-thirds suffered from mild to severe graft-versus-host-disease (GVHD), which occurs when the transplanted bone marrow attacks the recipient's tissues. After an average of 1 1/2 years, 20% to 40% of the leukemia patients were still alive. Almost 30% of the patients with aplastic anemia were still alive. By Sep 1991, 66% of the patients had died, most from infection or GVHD. Only 14% died from a recurrence of their disease.

Published
1993

21. Interim Analysis of the Use of the Anti-Idiotype Breast Cancer Vaccine 11D10 (TriAb®) in Conjunction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer

Author

Reece, Donna E., Foon, Kenneth A., Battacharya-Chatterjee, Malaya, Adkins, Doug, Broun, E. Randolph, Connaghan, D. Gerald, Dipersio, John F., Holland, H. Kent, Howard, Dianna S., Hale, Greg A., Klingemann, Hans G., Munn, Rita K., Raptis, Anastasios, and Phillips, Gordon L.

Published
2001
Full Text
View/download PDF

22. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.

Author

Reid, Robin M., Baran, Andrea, Friedberg, Jonathan W., Phillips, Gordon L., Liesveld, Jane L., Becker, Michael W., Wedow, Lucy, Barr, Paul M., and Milner, Laurie A.

Subjects
HEMATOPOIETIC stem cell transplantation, LYMPHOMA treatment, CANCER chemotherapy, COST effectiveness, STEM cell transplantation
Abstract

High-dose BEAM chemotherapy ( BCNU, etoposide, Ara-C, and melphalan) followed by autologous hematopoietic stem cell transplantation is frequently used as consolidative therapy for patients with recurrent or refractory Hodgkin or non-Hodgkin lymphoma. The BEAM regimen has traditionally been administered over 6 days in the hospital, with patients remaining hospitalized until hematologic recovery and clinical stability. In an effort to reduce the length of hospitalization for these patients, our institution has transitioned from inpatient ( IP) to outpatient ( OP) administration of BEAM conditioning. Here, we report the results of an analysis of the feasibility, cost, complications, and outcomes for the initial group of patients who received OP BEAM compared to a prior cohort of patients who received IP BEAM. Patient and disease characteristics were comparable for the two cohorts, as were engraftment kinetics. Length of hospital stay was reduced by 6 days for the OP cohort ( P < 0.001), resulting in a cost savings of more than $17,000 per patient. Fewer complications occurred in the OP cohort, including severe enteritis ( P = 0.01), organ toxicities ( P = 0.01), and infections ( P = 0.04). Overall survival rate up to 3 years posttransplant was better for the OP cohort ( P = 0.02), likely due to differences in posttransplant therapies. We conclude that OP administration of BEAM conditioning is safe and may offer significant advantages, including decreased length of hospitalization, reduced costs, decreased risks for severe toxicities and infectious complications, and likely improvement in patient satisfaction and quality of life. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

23. Clonal hematopoiesis demonstrated by x-linked DNA polymorphisms after allogeneic bone marrow transplantation

Author

Turhan, Ali G., Humphries, R. Keith, Phillips, Gordon L., Eaves, Allen C., and Eaves, Connie J.

Subjects
Hematopoietic stem cells -- Analysis, DNA -- Analysis, Homografts -- Research, Bone marrow -- Transplantation, Transplantation of organs, tissues, etc. -- Physiological aspects, Hematopoiesis -- Research, Hemoglobin polymorphisms -- Analysis
Abstract

Transplantation of bone marrow that is different from the marrow it replaces can successfully replace the old marrow and produce blood cells. All the patients in the investigation were being treated for leukemia or lymphoma. After transplantation, some of the blood of ten out of twelve patients showed traces of having been produced by the transplanted marrow. One of the other two patients had few or no blood cells produced by the transplanted marrow, while the other had most of his blood cells produced by the transplanted marrow. The second patient's blood remained in this condition for nine months.

Published
1989

24. Delphi-Panel Analysis of Appropriateness of High-Dose Chemotherapy and Blood Cell or Bone Marrow Autotransplants in Diffuse Large-Cell Lymphoma.

Author

Gale, Robert Peter, Park, Rolla Edward, Dubois, Robert, Bierman, Philip Jay, Fisher, Richard I., Loh, Kevin K., Peterson, Bruce A., Phillips, Gordon L., Portlock, Carol S., Rosenblum, Daniel, and Armitage, James O.

Subjects
AUTOGRAFTS, LYMPHOMAS
Abstract

Although high-dose chemotherapy and a blood cell or bone marrow autotransplant are commonly used to treat people with diffuse large-cell lymphoma, there is controversy whether this is better than conventional-dose chemotherapy. Subject-selection and time-to-treatment biases preclude comparison of data from uncontrolled trials and there are few date from randomized trials. We used a Delphi-panel group judgment process to determine appropriateness of high-dose chemotherapy and a blood cell or bone marrow transplant. Results were compared to those of randomized trials. Nine lymphoma experts from diverse geographic sites and practice settings were panelists. Boolean MEDLINE searches of lymphoma and chemotherapy and an autotransplant formed the dataset. Panelists were asked to rate apropriateness of high-dose chemotherapy and an autotransplant compared to conventional-dose chemotherapy. Clinical variables were permuted to define 80 clinical settings rated by the panelists on a 9-point ordinal scale. Results were used to determine an appropriateness index reflecting the mean and distribution of ratings. The relationship of appropriateness indices to permuted clinical variables was considered by analysis of variance and recursive partitioning. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

25. A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1α for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.

Author

Bernstein, Steven H., Eaves, Connie J., Herzig, Roger, Fay, Joseph, Lynch, Joseph, Phillips, Gordon L., Christiansen, Neal, Reece, Donna, Ericson, Solveig, Stephan, Margaret, Kovalsky, Matthew, Hawkins, Kim, Rasmussen, Henrik, DeVos, Arjen, and Herzig, Geoffrey P.

Published
1997
Full Text
View/download PDF

30. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.

Author

Phillips, Gordon L., Fay, Joseph W., Herzig, Geoffrey P., Herzig, Roger H., Weiner, Roy S., Wolff, Steven N., Lazarus, Hillard M., Karanes, Chatachada, Ross, Warren E., Kramer, Barnett S., Phillips, G L, Fay, J W, Herzig, G P, Herzig, R H, Weiner, R S, Wolff, S N, Lazarus, H M, Karanes, C, Ross, W E, and Kramer, B S

Published
1983
Full Text
View/download PDF

40. How do we define cure of diabetes?

Author

Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS, Buse, John B, Caprio, Sonia, Cefalu, William T, Ceriello, Antonio, Del Prato, Stefano, Inzucchi, Silvio E, McLaughlin, Sue, and Phillips, Gordon L 2nd

Published
2009
Full Text
View/download PDF

43. Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma

Author

van Besien, Koen, Sobocinski, Kathleen A., Rowlings, Philip A., Murphy, Sandra C., Armitage, James O., Bishop, Michael R., Chaekal, Ok-kyong, Gale, Robert Peter, Klein, John P., Lazarus, Hillard M., McCarthy, Philip L., Jr, Raemaekers, John M.M., Reiffers, Josy, Phillips, Gordon L., Schattenberg, Anton V.M.B., Verdonck, Leo F., Vose, Julie M., and Horowitz, Mary M.

Published
1998
Full Text
View/download PDF

48. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma

Author

Biswas, Tithi, Culakova, Eva, Friedberg, Jonathan W., Kelly, Jennifer L., Dhakal, Sughosh, Liesveld, Jane, Phillips, Gordon L., and Constine, Louis S.

Subjects
*CANCER radiotherapy, *RADIATION dosimetry, *CANCER chemotherapy, *AUTOTRANSPLANTATION, *STEM cell transplantation, *SURVIVAL, *HODGKIN'S disease treatment
Abstract

Abstract: Background and purpose: Patients with recurrent or primary refractory Hodgkin lymphoma (HL) treated with high dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) commonly relapse post-ASCT in previous disease sites. We sought to evaluate involved field radiation therapy (IFRT) following ASCT and patterns of recurrence, overall survival (OS), and disease specific survival (DSS). Methods and materials: Between May 1993 and October 2003, 62 (n =66) evaluable patients with refractory/relapsed HL underwent HDT followed by ASCT. Thirty-two (52%) patients received IFRT following transplant. Survival was calculated from the day of hematopoietic stem cell infusion. Results: Median follow-up was 2.3years (range 0.03–11.56). Estimated 3-year OS (p =0.05) and DSS (p =0.08) were 69.6% and 82.1% with IFRT and 40% and 57.6% without IFRT on univariate analysis. B-symptoms were adverse on univariate (p =0.007) and multivariate (p =0.01) analysis. HL patients who received IFRT following ASCT had improved local control in areas of previously recurrent disease (p =0.03). Conclusion: OS and DSS showed marginal benefit at 3years. Given the retrospective nature of our study and attendant selection bias that can be both positive and negative, a future prospective study is warranted to better understand the value of IFRT in the transplant setting. [Copyright &y& Elsevier]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results